Which endpoints are important to the G-BA and IQWiG?
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:
Category: News and updates
Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
Want to know the key differences between SHI and private health insurance in Germany?
Hi! Welcome to the last article in the 3-part series on reimbursement. This time, I’m sharing some facts about private health insurance
Happy with your knowledge on the reimbursement of medical devices in Germany?
Hello again, and welcome to the second post in the 3-part series on reimbursement. Last week, we focused on the reimbursement of
Are you interested in drug reimbursement in Germany? – Get up to speed here
Welcome to the start of our 3-part series on reimbursement, starting with reimbursement of drugs in Germany. Today, you will learn about: